Spotlight On... Novartis faces whistleblower claims of bribery in Turkey; Acadia's Nuplazid wins FDA panel backing; Florida nurse practitioners on verge of winning script powers; and more...

Novartis ($NVS) faces bribery allegations in yet another country. A whistleblower has accused the Swiss drugmaker of paying bribes in Turkey to increase prescriptions of its drugs, Reuters reports. More

> An FDA advisory panel backed Acadia Pharmaceuticals' new Parkinson's disease drug Nuplazid for approval in a 12-2 vote. Report

> The time the FDA takes to review new drug applications is steadily decreasing, to an average of about 10 months in 2014, with the biggest gains in oncology. Report

> Lawmakers in Florida, the only remaining state that prohibits nurse practitioners from prescribing meds, passed a bill to grant them that power. Report

> Opko Health got a rejection letter from the FDA on its application for approval of its thyroid drug Rayaldee. Release

And Finally... Genetic testing to choose drug therapies helps treatment work better, but has to be repeated with relapses to keep benefits coming. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.